{"id": "article-23208_0", "title": "Hyperprolactinemia -- Continuing Education Activity", "content": "When the amount of serum prolactin exceeds the upper limit, we call it hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea. This activity reviews the cause and presentation of hyperprolactinemia and stresses the importance of the interprofessional team in its management.", "contents": "Hyperprolactinemia -- Continuing Education Activity. When the amount of serum prolactin exceeds the upper limit, we call it hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea. This activity reviews the cause and presentation of hyperprolactinemia and stresses the importance of the interprofessional team in its management."}
{"id": "article-23208_1", "title": "Hyperprolactinemia -- Continuing Education Activity", "content": "Objectives: Review the causes of hyperprolactinemia. Describe the evaluation of a patient with hyperprolactinemia. Summarize the treatment of hyperprolactinemia. Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by hyperprolactinemia. Access free multiple choice questions on this topic.", "contents": "Hyperprolactinemia -- Continuing Education Activity. Objectives: Review the causes of hyperprolactinemia. Describe the evaluation of a patient with hyperprolactinemia. Summarize the treatment of hyperprolactinemia. Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by hyperprolactinemia. Access free multiple choice questions on this topic."}
{"id": "article-23208_2", "title": "Hyperprolactinemia -- Introduction", "content": "Prolactin hormone is\u00a0exclusively\u00a0synthesized\u00a0and secreted from lactotrophs\u00a0of the anterior pituitary gland. The secretion rate of prolactin is about 200 to 536 mcg/day/meter square [1] and the half-life is 25 to 50 minutes.\u00a0Prolactin\u00a0is metabolized\u00a0by the\u00a0liver (75%) and the kidney (25%). The basal level of prolactin in women averages 13 ng/ml and in men, it averages \u00a05 ng/ml. The upper normal limit of serum prolactin level in most laboratories is 15 to 20 ng/ml. When the amount of serum prolactin exceeds the upper limit, we call it\u00a0hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea.", "contents": "Hyperprolactinemia -- Introduction. Prolactin hormone is\u00a0exclusively\u00a0synthesized\u00a0and secreted from lactotrophs\u00a0of the anterior pituitary gland. The secretion rate of prolactin is about 200 to 536 mcg/day/meter square [1] and the half-life is 25 to 50 minutes.\u00a0Prolactin\u00a0is metabolized\u00a0by the\u00a0liver (75%) and the kidney (25%). The basal level of prolactin in women averages 13 ng/ml and in men, it averages \u00a05 ng/ml. The upper normal limit of serum prolactin level in most laboratories is 15 to 20 ng/ml. When the amount of serum prolactin exceeds the upper limit, we call it\u00a0hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea."}
{"id": "article-23208_3", "title": "Hyperprolactinemia -- Etiology", "content": "Physiological, pathological, or pharmacological conditions can cause hyperprolactinemia. [2] [3] Any condition that affects secretion and clearance of prolactin will cause hyperprolactinemia. Physiological hyperprolactinemia is transient and adaptive; whereas, pathological and pharmacological hyperprolactinemia are symptomatic with unwanted\u00a0long-term consequences.", "contents": "Hyperprolactinemia -- Etiology. Physiological, pathological, or pharmacological conditions can cause hyperprolactinemia. [2] [3] Any condition that affects secretion and clearance of prolactin will cause hyperprolactinemia. Physiological hyperprolactinemia is transient and adaptive; whereas, pathological and pharmacological hyperprolactinemia are symptomatic with unwanted\u00a0long-term consequences."}
{"id": "article-23208_4", "title": "Hyperprolactinemia -- Etiology -- Physiological Causes", "content": "Pregnancy Nipple stimulation and lactation Exercise Stress (hypoglycemia, myocardial infarction, surgery) Seizures Sleep Neonatal period Sexual intercourse", "contents": "Hyperprolactinemia -- Etiology -- Physiological Causes. Pregnancy Nipple stimulation and lactation Exercise Stress (hypoglycemia, myocardial infarction, surgery) Seizures Sleep Neonatal period Sexual intercourse"}
{"id": "article-23208_5", "title": "Hyperprolactinemia -- Etiology", "content": "During pregnancy, the\u00a0pituitary gland increases in size, also increasing the size of lactotrophs. The gland may double in size during pregnancy. [4] Serum prolactin increases throughout the pregnancy and reaches\u00a0a peak\u00a0at delivery. [5] It is probably because of increased serum estradiol concentration.\u00a0After\u00a0delivery, estradiol secretion decreases and the serum prolactin becomes normal with breastfeeding. In pregnancy, serum prolactin usually becomes 10 times normal with a range of 35 to 600 ng/ml at term [5] ;\u00a0prolactin in amniotic fluid is 100 times more compared to levels in maternal and fetal blood. [5]", "contents": "Hyperprolactinemia -- Etiology. During pregnancy, the\u00a0pituitary gland increases in size, also increasing the size of lactotrophs. The gland may double in size during pregnancy. [4] Serum prolactin increases throughout the pregnancy and reaches\u00a0a peak\u00a0at delivery. [5] It is probably because of increased serum estradiol concentration.\u00a0After\u00a0delivery, estradiol secretion decreases and the serum prolactin becomes normal with breastfeeding. In pregnancy, serum prolactin usually becomes 10 times normal with a range of 35 to 600 ng/ml at term [5] ;\u00a0prolactin in amniotic fluid is 100 times more compared to levels in maternal and fetal blood. [5]"}
{"id": "article-23208_6", "title": "Hyperprolactinemia -- Etiology", "content": "Nipple stimulation increases prolactin secretion which\u00a0is\u00a0mediated\u00a0by neural\u00a0pathways during breastfeeding. Prolactin secretion increases transiently with suckling reaching up to\u00a0300\u00a0ng/ml above baseline. The levels increase to 10 ng/ml above baseline in the first week and continue to rise for several months after delivery. [5]", "contents": "Hyperprolactinemia -- Etiology. Nipple stimulation increases prolactin secretion which\u00a0is\u00a0mediated\u00a0by neural\u00a0pathways during breastfeeding. Prolactin secretion increases transiently with suckling reaching up to\u00a0300\u00a0ng/ml above baseline. The levels increase to 10 ng/ml above baseline in the first week and continue to rise for several months after delivery. [5]"}
{"id": "article-23208_7", "title": "Hyperprolactinemia -- Etiology -- Pathological Causes", "content": "Pituitary Disease Prolactinoma Acromegaly Cushing disease Macroadenoma (compressive) Plurihormonal adenoma Lymphocytic hypophysitis Parasellar mass Macroprolactinemia", "contents": "Hyperprolactinemia -- Etiology -- Pathological Causes. Pituitary Disease Prolactinoma Acromegaly Cushing disease Macroadenoma (compressive) Plurihormonal adenoma Lymphocytic hypophysitis Parasellar mass Macroprolactinemia"}
{"id": "article-23208_8", "title": "Hyperprolactinemia -- Etiology -- Pathological Causes", "content": "Prolactinoma is a benign tumor of lactotrophs. It accounts for up to 40% of all pituitary adenomas. It can present with any level of prolactin elevation from mild elevation to 50,000 ng/ml. In contrast, prolactin elevation from other causes rarely\u00a0exceeds 200 ng/ml. [6] Hypothalamic Disease - Stalk Damage Tumors like craniopharyngioma, suprasellar pituitary mass extension, meningioma, dysgerminoma, hypothalamic metastases Granulomas (sarcoidosis, tuberculosis) Infiltrative disease (histiocytosis disease) Rathke's cyst Pituitary stalk\u00a0transection (Sellar surgery, head trauma) Cranial Irradiation Pharmacological Causes", "contents": "Hyperprolactinemia -- Etiology -- Pathological Causes. Prolactinoma is a benign tumor of lactotrophs. It accounts for up to 40% of all pituitary adenomas. It can present with any level of prolactin elevation from mild elevation to 50,000 ng/ml. In contrast, prolactin elevation from other causes rarely\u00a0exceeds 200 ng/ml. [6] Hypothalamic Disease - Stalk Damage Tumors like craniopharyngioma, suprasellar pituitary mass extension, meningioma, dysgerminoma, hypothalamic metastases Granulomas (sarcoidosis, tuberculosis) Infiltrative disease (histiocytosis disease) Rathke's cyst Pituitary stalk\u00a0transection (Sellar surgery, head trauma) Cranial Irradiation Pharmacological Causes"}
{"id": "article-23208_9", "title": "Hyperprolactinemia -- Etiology -- Pathological Causes", "content": "Estrogen therapy Thyrotropin-releasing hormone Antipsychotic/dopamine\u00a0receptor blocking agents:\u00a0 risperidone, haloperidol, fluphenazine, among others Antiemetic/dopamine receptor blocking agents:\u00a0metoclopramide, domperidone, prochlorperazine Tricyclic antidepressant, selective serotonin receptor inhibitor: amitriptyline, clomipramine, fluoxetine Anticonvulsant: Phenytoin Antihypertensive: Verapamil, methyldopa, labetalol H2 Antihistamines: Cimetidine, ranitidine Opioid analgesics: Methadone, morphine, apomorphine, heroin Cholinergic agent: Physostigmine Systemic Disorder Chronic renal failure Polycystic ovarian disease Liver cirrhosis Pseudocyesis Reflex causes: Chest wall trauma, surgery, herpes zoster Primary hypothyroidism", "contents": "Hyperprolactinemia -- Etiology -- Pathological Causes. Estrogen therapy Thyrotropin-releasing hormone Antipsychotic/dopamine\u00a0receptor blocking agents:\u00a0 risperidone, haloperidol, fluphenazine, among others Antiemetic/dopamine receptor blocking agents:\u00a0metoclopramide, domperidone, prochlorperazine Tricyclic antidepressant, selective serotonin receptor inhibitor: amitriptyline, clomipramine, fluoxetine Anticonvulsant: Phenytoin Antihypertensive: Verapamil, methyldopa, labetalol H2 Antihistamines: Cimetidine, ranitidine Opioid analgesics: Methadone, morphine, apomorphine, heroin Cholinergic agent: Physostigmine Systemic Disorder Chronic renal failure Polycystic ovarian disease Liver cirrhosis Pseudocyesis Reflex causes: Chest wall trauma, surgery, herpes zoster Primary hypothyroidism"}
{"id": "article-23208_10", "title": "Hyperprolactinemia -- Etiology -- Genetic", "content": "Inactivating prolactin receptor mutation [7] Ectopic Production Bronchogenic carcinoma and hypernephromas [8] Idiopathic", "contents": "Hyperprolactinemia -- Etiology -- Genetic. Inactivating prolactin receptor mutation [7] Ectopic Production Bronchogenic carcinoma and hypernephromas [8] Idiopathic"}
{"id": "article-23208_11", "title": "Hyperprolactinemia -- Epidemiology", "content": "Hyperprolactinemia\u00a0occurs in less than 1% of the general population and 5% to 14% of patients presenting with secondary amenorrhea. [9] The most common type is a prolactin-secreting tumor (prolactinoma), accounting for up to 40% of all clinically recognized pituitary adenomas. [10] The mean prevalence of prolactinoma is estimated to be around 30 per 100,000 in women and 10 per 100,000 in men; with peak prevalence in women aged 25 to 34 years. [10] Clinical manifestations in women are more obvious and present earlier than in men.", "contents": "Hyperprolactinemia -- Epidemiology. Hyperprolactinemia\u00a0occurs in less than 1% of the general population and 5% to 14% of patients presenting with secondary amenorrhea. [9] The most common type is a prolactin-secreting tumor (prolactinoma), accounting for up to 40% of all clinically recognized pituitary adenomas. [10] The mean prevalence of prolactinoma is estimated to be around 30 per 100,000 in women and 10 per 100,000 in men; with peak prevalence in women aged 25 to 34 years. [10] Clinical manifestations in women are more obvious and present earlier than in men."}
{"id": "article-23208_12", "title": "Hyperprolactinemia -- Pathophysiology", "content": "Prolactin is responsible for\u00a0milk production during pregnancy and lactation. Along with estrogen, progesterone, possibly insulin-like growth factor-1 (IGF-1), and placental hormones, prolactin stimulates breast alveolar element proliferation in pregnancy. [11] Lactation is suppressed\u00a0during pregnancy due to\u00a0the high level of estrogen. Active lactation occurs because of decreased estrogen and progesterone levels and an increase in prolactin levels after delivery. During pregnancy, estrogen has a stimulatory effect on the proliferation of lactotrophs, thereby\u00a0secreting prolactin. Lactation results in amenorrhea and secondary infertility because of prolactin-mediated suppression of gonadotropins.", "contents": "Hyperprolactinemia -- Pathophysiology. Prolactin is responsible for\u00a0milk production during pregnancy and lactation. Along with estrogen, progesterone, possibly insulin-like growth factor-1 (IGF-1), and placental hormones, prolactin stimulates breast alveolar element proliferation in pregnancy. [11] Lactation is suppressed\u00a0during pregnancy due to\u00a0the high level of estrogen. Active lactation occurs because of decreased estrogen and progesterone levels and an increase in prolactin levels after delivery. During pregnancy, estrogen has a stimulatory effect on the proliferation of lactotrophs, thereby\u00a0secreting prolactin. Lactation results in amenorrhea and secondary infertility because of prolactin-mediated suppression of gonadotropins."}
{"id": "article-23208_13", "title": "Hyperprolactinemia -- Pathophysiology", "content": "The hypothalamic control of prolactin secretion is\u00a0mostly\u00a0inhibitory\u00a0by prolactin inhibiting factor\u00a0and dopamine is the main inhibitor that acts via type 2 dopamine (D2) receptor [12] located\u00a0on lactotrophs. Thyrotropin-releasing hormone (TRH) is a potent prolactin-releasing factor. There is an elevated\u00a0response to both thyroid-stimulating hormone (TSH) and prolactin in primary hypothyroidism. Other prolactin-releasing factors are a vasoactive intestinal peptide (VIP), endothelial growth factor, and dopamine antagonists. Drugs like neuroleptics elevate prolactin because of their dopamine receptor\u00a0antagonist property, and atypical antipsychotics act by antagonizing both secretions of serotonin and dopamine. Pituitary or sellar tumors\u00a0inhibit dopamine-induced hyperprolactinemia because of\u00a0pressure on the pituitary stalk or interruption of the vascular connections between the pituitary and hypothalamus.", "contents": "Hyperprolactinemia -- Pathophysiology. The hypothalamic control of prolactin secretion is\u00a0mostly\u00a0inhibitory\u00a0by prolactin inhibiting factor\u00a0and dopamine is the main inhibitor that acts via type 2 dopamine (D2) receptor [12] located\u00a0on lactotrophs. Thyrotropin-releasing hormone (TRH) is a potent prolactin-releasing factor. There is an elevated\u00a0response to both thyroid-stimulating hormone (TSH) and prolactin in primary hypothyroidism. Other prolactin-releasing factors are a vasoactive intestinal peptide (VIP), endothelial growth factor, and dopamine antagonists. Drugs like neuroleptics elevate prolactin because of their dopamine receptor\u00a0antagonist property, and atypical antipsychotics act by antagonizing both secretions of serotonin and dopamine. Pituitary or sellar tumors\u00a0inhibit dopamine-induced hyperprolactinemia because of\u00a0pressure on the pituitary stalk or interruption of the vascular connections between the pituitary and hypothalamus."}
{"id": "article-23208_14", "title": "Hyperprolactinemia -- Pathophysiology", "content": "Prolactin causes inhibition of gonadotropin-releasing hormone (GnRH) leading to\u00a0inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. [13] Symptoms of hypogonadism depend upon the magnitude of prolactin elevation.\u00a0Serum prolactin greater than 100 ng/dl will have overt hypogonadism with the presentation of amenorrhea, hot flashes, and vaginal dryness. Serum prolactin between 50 to 100 ng/dl may cause amenorrhea or oligomenorrhea and serum prolactin 20 to 50 ng/dl may only shorten the luteal phase because of insufficient progesterone secretion. [14] [15]", "contents": "Hyperprolactinemia -- Pathophysiology. Prolactin causes inhibition of gonadotropin-releasing hormone (GnRH) leading to\u00a0inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. [13] Symptoms of hypogonadism depend upon the magnitude of prolactin elevation.\u00a0Serum prolactin greater than 100 ng/dl will have overt hypogonadism with the presentation of amenorrhea, hot flashes, and vaginal dryness. Serum prolactin between 50 to 100 ng/dl may cause amenorrhea or oligomenorrhea and serum prolactin 20 to 50 ng/dl may only shorten the luteal phase because of insufficient progesterone secretion. [14] [15]"}
{"id": "article-23208_15", "title": "Hyperprolactinemia -- History and Physical", "content": "The symptoms of hyperprolactinemia can be due to a direct effect of excess prolactin or the compressive effect of the structural lesion. Hyperprolactinemia causes typical symptoms in premenopausal women and men but not in postmenopausal women.\u00a0 Reproductive dysfunction and galactorrhea are the hallmarks of hyperprolactinemia. Children and adolescent may have growth arrest, pubertal delay, and primary amenorrhea.", "contents": "Hyperprolactinemia -- History and Physical. The symptoms of hyperprolactinemia can be due to a direct effect of excess prolactin or the compressive effect of the structural lesion. Hyperprolactinemia causes typical symptoms in premenopausal women and men but not in postmenopausal women.\u00a0 Reproductive dysfunction and galactorrhea are the hallmarks of hyperprolactinemia. Children and adolescent may have growth arrest, pubertal delay, and primary amenorrhea."}
{"id": "article-23208_16", "title": "Hyperprolactinemia -- History and Physical -- Women", "content": "Menstrual disturbance: Oligomenorrhea, amenorrhea, menorrhagia or infertility Galactorrhea: Most women who have hyperprolactinemia may not have galactorrhea Low bone mass", "contents": "Hyperprolactinemia -- History and Physical -- Women. Menstrual disturbance: Oligomenorrhea, amenorrhea, menorrhagia or infertility Galactorrhea: Most women who have hyperprolactinemia may not have galactorrhea Low bone mass"}
{"id": "article-23208_17", "title": "Hyperprolactinemia -- History and Physical -- Men", "content": "Hypogonadotropic\u00a0hypogonadism: Decreased libido, impotence, infertility, oligospermia or gynecomastia [16] Erectile dysfunction Galactorrhea: Rare Low bone mass Sign and Symptoms Caused by Mass Effect Headache Visual field defect External ophthalmoplegic", "contents": "Hyperprolactinemia -- History and Physical -- Men. Hypogonadotropic\u00a0hypogonadism: Decreased libido, impotence, infertility, oligospermia or gynecomastia [16] Erectile dysfunction Galactorrhea: Rare Low bone mass Sign and Symptoms Caused by Mass Effect Headache Visual field defect External ophthalmoplegic"}
{"id": "article-23208_18", "title": "Hyperprolactinemia -- Evaluation", "content": "The clinician starts the evaluation of suspected hyperprolactinemia with serum prolactin level, ideally with a fasting mid-morning sample.\u00a0An increase in prolactin secretion\u00a0is associated with sleep. However, it is not part of the circadian rhythm. The peak level of prolactin is usually between 4 AM and 7 AM. The ideal time to measure prolactin is during the midmorning hours and in the fasting state.\u00a0Food has a minimal effect on the serum concentration of prolactin.\u00a0So, fasting is not always\u00a0an essential condition to measure serum prolactin levels except when\u00a0there is a mild elevation on the initial value. If serum prolactin is elevated, the next step is to determine the cause in the following order: Exclusion of physiological causes Exclusion of pharmacological causes Neuroradiological imaging of the hypothalamic-pituitary region.", "contents": "Hyperprolactinemia -- Evaluation. The clinician starts the evaluation of suspected hyperprolactinemia with serum prolactin level, ideally with a fasting mid-morning sample.\u00a0An increase in prolactin secretion\u00a0is associated with sleep. However, it is not part of the circadian rhythm. The peak level of prolactin is usually between 4 AM and 7 AM. The ideal time to measure prolactin is during the midmorning hours and in the fasting state.\u00a0Food has a minimal effect on the serum concentration of prolactin.\u00a0So, fasting is not always\u00a0an essential condition to measure serum prolactin levels except when\u00a0there is a mild elevation on the initial value. If serum prolactin is elevated, the next step is to determine the cause in the following order: Exclusion of physiological causes Exclusion of pharmacological causes Neuroradiological imaging of the hypothalamic-pituitary region."}
{"id": "article-23208_19", "title": "Hyperprolactinemia -- Evaluation", "content": "An extensive history and physical examination are important to exclude causes of hyperprolactinemia and inquire about signs and symptoms of\u00a0hyperprolactinemia.", "contents": "Hyperprolactinemia -- Evaluation. An extensive history and physical examination are important to exclude causes of hyperprolactinemia and inquire about signs and symptoms of\u00a0hyperprolactinemia."}
{"id": "article-23208_20", "title": "Hyperprolactinemia -- Evaluation -- Laboratory Tests", "content": "Following tests are generally needed\u00a0depending upon gender, age, and clinical presentation: Serum prolactin Thyroid function test Renal function test Insulin-like growth factor-1 (IGF-1) Adrenocorticotrophic hormone (ACTH) Luteinizing\u00a0hormone (LH) Follicle-stimulating\u00a0hormone (FSH) Testosterone/estradiol Pregnancy test", "contents": "Hyperprolactinemia -- Evaluation -- Laboratory Tests. Following tests are generally needed\u00a0depending upon gender, age, and clinical presentation: Serum prolactin Thyroid function test Renal function test Insulin-like growth factor-1 (IGF-1) Adrenocorticotrophic hormone (ACTH) Luteinizing\u00a0hormone (LH) Follicle-stimulating\u00a0hormone (FSH) Testosterone/estradiol Pregnancy test"}
{"id": "article-23208_21", "title": "Hyperprolactinemia -- Evaluation -- Imaging Test", "content": "Magnetic\u00a0resonance imaging (MRI) of the pituitary with contrast is the preferred imaging study. Visual field testing\u00a0should be done\u00a0in case of macroadenoma and tumor that is adjacent to/or compressing to optic chiasma.", "contents": "Hyperprolactinemia -- Evaluation -- Imaging Test. Magnetic\u00a0resonance imaging (MRI) of the pituitary with contrast is the preferred imaging study. Visual field testing\u00a0should be done\u00a0in case of macroadenoma and tumor that is adjacent to/or compressing to optic chiasma."}
{"id": "article-23208_22", "title": "Hyperprolactinemia -- Evaluation -- Pitfalls in Diagnosis", "content": "Hook Effect: It is\u00a0because of\u00a0an artifact\u00a0in the\u00a0immunoradiometric\u00a0assay giving a falsely low concentration of prolactin.\u00a0Hook effect should be kept\u00a0in mind with large pituitary adenoma with mild or moderate\u00a0elevation in prolactin. When there is\u00a0very\u00a0high serum prolactin concentration, both the capture and tracer antibodies used in\u00a0immunoradiometric\u00a0assays become saturated, preventing the binding of the two, to create a sandwich. Then the test result will read low. This\u00a0effect can\u00a0be\u00a0overcome\u00a0by repeating the test using a 1:100 dilution of serum.\u00a0This artifact is uncommon.", "contents": "Hyperprolactinemia -- Evaluation -- Pitfalls in Diagnosis. Hook Effect: It is\u00a0because of\u00a0an artifact\u00a0in the\u00a0immunoradiometric\u00a0assay giving a falsely low concentration of prolactin.\u00a0Hook effect should be kept\u00a0in mind with large pituitary adenoma with mild or moderate\u00a0elevation in prolactin. When there is\u00a0very\u00a0high serum prolactin concentration, both the capture and tracer antibodies used in\u00a0immunoradiometric\u00a0assays become saturated, preventing the binding of the two, to create a sandwich. Then the test result will read low. This\u00a0effect can\u00a0be\u00a0overcome\u00a0by repeating the test using a 1:100 dilution of serum.\u00a0This artifact is uncommon."}
{"id": "article-23208_23", "title": "Hyperprolactinemia -- Evaluation -- Pitfalls in Diagnosis", "content": "Macroprolactin represents large circulating aggregates of prolactin and antibodies of size about 150\u00a0kD; whereas, native prolactin in serum is 23 kD. [17] These complexes are detectable in test assay but are biologically inactive.\u00a0They can\u00a0be\u00a0misdiagnosed as prolactin hypersecretion. [18] . Clinicians can avoid this misdiagnosis by precipitating\u00a0macroprolactin\u00a0by\u00a0pretreating\u00a0with polyethylene glycol before measuring prolactin.", "contents": "Hyperprolactinemia -- Evaluation -- Pitfalls in Diagnosis. Macroprolactin represents large circulating aggregates of prolactin and antibodies of size about 150\u00a0kD; whereas, native prolactin in serum is 23 kD. [17] These complexes are detectable in test assay but are biologically inactive.\u00a0They can\u00a0be\u00a0misdiagnosed as prolactin hypersecretion. [18] . Clinicians can avoid this misdiagnosis by precipitating\u00a0macroprolactin\u00a0by\u00a0pretreating\u00a0with polyethylene glycol before measuring prolactin."}
{"id": "article-23208_24", "title": "Hyperprolactinemia -- Treatment / Management", "content": "Treatment of hyperprolactinemia depends upon the cause. Once the physiological cause of hyperprolactinemia is excluded, we should look for other possible systemic causes and address them for the\u00a0symptomatic patient. Here, we are discussing treatment options based on etiology.", "contents": "Hyperprolactinemia -- Treatment / Management. Treatment of hyperprolactinemia depends upon the cause. Once the physiological cause of hyperprolactinemia is excluded, we should look for other possible systemic causes and address them for the\u00a0symptomatic patient. Here, we are discussing treatment options based on etiology."}
{"id": "article-23208_25", "title": "Hyperprolactinemia -- Treatment / Management -- Etiology Type", "content": "Hypothyroidism The patient should\u00a0be treated with thyroid replacement therapy and confirm the normalization of prolactin level after treatment. Drug-Induced Hyperprolactinemia", "contents": "Hyperprolactinemia -- Treatment / Management -- Etiology Type. Hypothyroidism The patient should\u00a0be treated with thyroid replacement therapy and confirm the normalization of prolactin level after treatment. Drug-Induced Hyperprolactinemia"}
{"id": "article-23208_26", "title": "Hyperprolactinemia -- Treatment / Management -- Etiology Type", "content": "Treatment is only necessary if patients develop hypogonadism, osteoporosis, or troublesome galactorrhea. [19] If hyperprolactinemia is suspected\u00a0because of drugs, it should\u00a0be discontinued\u00a0temporarily, if possible, to see if prolactin level normalizes.\u00a0If medication cannot\u00a0be discontinued,\u00a0especially antipsychotics, it should be changed to a different antipsychotics that do not increase prolactin, e.g., quetiapine. If that is not possible, the addition of dopamine agonists should be considered.\u00a0These changes should\u00a0be made\u00a0in consultation with\u00a0a psychiatrist. The addition of estradiol in women and testosterone in men can be considered\u00a0for hypogonadism and low bone mass.\u00a0If prolactin level does not\u00a0normalize after stopping meds or if discontinuation of meds is not possible, pituitary MRI should\u00a0be done. Hypothalamic Disease: Stalk Damage Removal of the cause should be the first choice; if not,\u00a0hyperprolactinemia should\u00a0be treated with the dopamine agonist. Idiopathic Hyperprolactinemia", "contents": "Hyperprolactinemia -- Treatment / Management -- Etiology Type. Treatment is only necessary if patients develop hypogonadism, osteoporosis, or troublesome galactorrhea. [19] If hyperprolactinemia is suspected\u00a0because of drugs, it should\u00a0be discontinued\u00a0temporarily, if possible, to see if prolactin level normalizes.\u00a0If medication cannot\u00a0be discontinued,\u00a0especially antipsychotics, it should be changed to a different antipsychotics that do not increase prolactin, e.g., quetiapine. If that is not possible, the addition of dopamine agonists should be considered.\u00a0These changes should\u00a0be made\u00a0in consultation with\u00a0a psychiatrist. The addition of estradiol in women and testosterone in men can be considered\u00a0for hypogonadism and low bone mass.\u00a0If prolactin level does not\u00a0normalize after stopping meds or if discontinuation of meds is not possible, pituitary MRI should\u00a0be done. Hypothalamic Disease: Stalk Damage Removal of the cause should be the first choice; if not,\u00a0hyperprolactinemia should\u00a0be treated with the dopamine agonist. Idiopathic Hyperprolactinemia"}
{"id": "article-23208_27", "title": "Hyperprolactinemia -- Treatment / Management -- Etiology Type", "content": "Idiopathic hyperprolactinemia is treated with the\u00a0dopamine agonist. However, these patients are relatively resistant to dopamine agonists. Dosage can be adjusted to keep the lowest possible dose with the\u00a0normal\u00a0level of prolactin. If the patient attains normal prolactin on the\u00a0lowest dose of a dopamine agonist for 2 years, the\u00a0drug\u00a0can be discontinued as a trial. Macroprolactinemia It does not require treatment. Prolactinoma It has medical, surgical, and radiation treatment.", "contents": "Hyperprolactinemia -- Treatment / Management -- Etiology Type. Idiopathic hyperprolactinemia is treated with the\u00a0dopamine agonist. However, these patients are relatively resistant to dopamine agonists. Dosage can be adjusted to keep the lowest possible dose with the\u00a0normal\u00a0level of prolactin. If the patient attains normal prolactin on the\u00a0lowest dose of a dopamine agonist for 2 years, the\u00a0drug\u00a0can be discontinued as a trial. Macroprolactinemia It does not require treatment. Prolactinoma It has medical, surgical, and radiation treatment."}
{"id": "article-23208_28", "title": "Hyperprolactinemia -- Treatment / Management -- Medical Treatment", "content": "Endocrine society guideline recommends against treatment with a dopamine agonist for asymptomatic microadenoma but recommends\u00a0dopamine agonist therapy to decrease prolactin levels, tumor size, and normalize gonadal function for symptomatic patients with microadenomas or macroadenomas.\u00a0Cabergoline\u00a0is preferred\u00a0to other dopamine agonists due to\u00a0higher efficacy in normalizing prolactin levels\u00a0and tumor shrinkage", "contents": "Hyperprolactinemia -- Treatment / Management -- Medical Treatment. Endocrine society guideline recommends against treatment with a dopamine agonist for asymptomatic microadenoma but recommends\u00a0dopamine agonist therapy to decrease prolactin levels, tumor size, and normalize gonadal function for symptomatic patients with microadenomas or macroadenomas.\u00a0Cabergoline\u00a0is preferred\u00a0to other dopamine agonists due to\u00a0higher efficacy in normalizing prolactin levels\u00a0and tumor shrinkage"}
{"id": "article-23208_29", "title": "Hyperprolactinemia -- Treatment / Management -- Medical Treatment", "content": "Cabergoline\u00a0and bromocriptine are commonly used dopamine agonists.\u00a0Quinagolide is not available in the United States but used in some other countries. Pergolide\u00a0had been withdrawn from the United States because of concern of valvular heart disease. Cabergoline is the first choice because of its efficacy and fewer side effects. [20] Bromocriptine is preferred\u00a0during pregnancy because of more favorable data than cabergoline. [10] Cabergoline\u00a0has a long duration of action than bromocriptine and is administered once or twice a week. Bromocriptine is administered\u00a0once daily. Common side effects are nausea, vomiting, nasal stiffness, digital vasospasm, depression, and postural hypotension.\u00a0High doses of dopamine agonists are associated with a risk of heart valve regurgitation. [21] Dopamine agonist\u00a0therapy can\u00a0be tapered and discontinued after 2 years of continuous therapy if serum prolactin level is normal and no adenoma is visible in magnetic resonance imaging (MRI).", "contents": "Hyperprolactinemia -- Treatment / Management -- Medical Treatment. Cabergoline\u00a0and bromocriptine are commonly used dopamine agonists.\u00a0Quinagolide is not available in the United States but used in some other countries. Pergolide\u00a0had been withdrawn from the United States because of concern of valvular heart disease. Cabergoline is the first choice because of its efficacy and fewer side effects. [20] Bromocriptine is preferred\u00a0during pregnancy because of more favorable data than cabergoline. [10] Cabergoline\u00a0has a long duration of action than bromocriptine and is administered once or twice a week. Bromocriptine is administered\u00a0once daily. Common side effects are nausea, vomiting, nasal stiffness, digital vasospasm, depression, and postural hypotension.\u00a0High doses of dopamine agonists are associated with a risk of heart valve regurgitation. [21] Dopamine agonist\u00a0therapy can\u00a0be tapered and discontinued after 2 years of continuous therapy if serum prolactin level is normal and no adenoma is visible in magnetic resonance imaging (MRI)."}
{"id": "article-23208_30", "title": "Hyperprolactinemia -- Treatment / Management -- Surgery/Radiation Treatment", "content": "Most of the\u00a0prolactinomas are treated with medical therapy only. Surgery and radiotherapy\u00a0are\u00a0reserved for those who are resistant to medical therapy with the\u00a0dopamine agonists.\u00a0Endoscopic endonasal\u00a0transsphenoidal\u00a0surgery is the preferred surgical method. Prophylactic surgery is considered\u00a0in women with large prolactinoma\u00a0which potentially threatens vision during pregnancy. [22] Adjuvant radiation therapy should be considered\u00a0for residual tumor. Gamma knife stereotactic radiosurgery is often effective in treating prolactinomas resistant to or intolerant of dopamine agonists. [23]", "contents": "Hyperprolactinemia -- Treatment / Management -- Surgery/Radiation Treatment. Most of the\u00a0prolactinomas are treated with medical therapy only. Surgery and radiotherapy\u00a0are\u00a0reserved for those who are resistant to medical therapy with the\u00a0dopamine agonists.\u00a0Endoscopic endonasal\u00a0transsphenoidal\u00a0surgery is the preferred surgical method. Prophylactic surgery is considered\u00a0in women with large prolactinoma\u00a0which potentially threatens vision during pregnancy. [22] Adjuvant radiation therapy should be considered\u00a0for residual tumor. Gamma knife stereotactic radiosurgery is often effective in treating prolactinomas resistant to or intolerant of dopamine agonists. [23]"}
{"id": "article-23208_31", "title": "Hyperprolactinemia -- Differential Diagnosis", "content": "Possible causes of hyperprolactinemia have been mentioned\u00a0in the etiology section. In clinical practice, it is important to exclude two important causes of hyperprolactinemia. They are hypothyroidism and the use of drugs that inhibit dopamine. Cirrhosis Dopamine antagonist medications Hypothalamic disease Idiopathic hyperprolactinemia Pituitary tumors Pregnancy Primary hypothyroidism Prolactinoma Renal failure", "contents": "Hyperprolactinemia -- Differential Diagnosis. Possible causes of hyperprolactinemia have been mentioned\u00a0in the etiology section. In clinical practice, it is important to exclude two important causes of hyperprolactinemia. They are hypothyroidism and the use of drugs that inhibit dopamine. Cirrhosis Dopamine antagonist medications Hypothalamic disease Idiopathic hyperprolactinemia Pituitary tumors Pregnancy Primary hypothyroidism Prolactinoma Renal failure"}
{"id": "article-23208_32", "title": "Hyperprolactinemia -- Prognosis", "content": "Most\u00a0patients with micro prolactinomas\u00a0have\u00a0good prognosis and normalize prolactin levels with treatment. These\u00a0patients can be managed\u00a0with medical therapy for a\u00a0prolonged period. The success of the pituitary surgery also depends upon the size of the tumor, the serum prolactin level, and the experience of the neurosurgeon. The success rate of pituitary surgery is related inversely to tumor size and prolactin levels. [24] Although\u00a0micro prolactinoma surgery has a\u00a0high success rate, the recurrence of hyperprolactinemia is relatively\u00a0high [25] which is about 17% in patients initially considered cured. In the case of macroprolactinoma,\u00a0around 50% of the patients are in remission after the surgery.\u00a0In the case of invasive tumors, complete resection may not be possible, and prolactin normalizes in only 32% of patients with a recurrence rate of about 19%.", "contents": "Hyperprolactinemia -- Prognosis. Most\u00a0patients with micro prolactinomas\u00a0have\u00a0good prognosis and normalize prolactin levels with treatment. These\u00a0patients can be managed\u00a0with medical therapy for a\u00a0prolonged period. The success of the pituitary surgery also depends upon the size of the tumor, the serum prolactin level, and the experience of the neurosurgeon. The success rate of pituitary surgery is related inversely to tumor size and prolactin levels. [24] Although\u00a0micro prolactinoma surgery has a\u00a0high success rate, the recurrence of hyperprolactinemia is relatively\u00a0high [25] which is about 17% in patients initially considered cured. In the case of macroprolactinoma,\u00a0around 50% of the patients are in remission after the surgery.\u00a0In the case of invasive tumors, complete resection may not be possible, and prolactin normalizes in only 32% of patients with a recurrence rate of about 19%."}
{"id": "article-23208_33", "title": "Hyperprolactinemia -- Complications", "content": "Mass effect leading to visual deficits, cranial nerve palsies and pituitary apoplexy Infertility Osteoporosis Blindness Complications related to cerebrospinal fluid (CSF) leak and hypopituitarism Hypogonadism", "contents": "Hyperprolactinemia -- Complications. Mass effect leading to visual deficits, cranial nerve palsies and pituitary apoplexy Infertility Osteoporosis Blindness Complications related to cerebrospinal fluid (CSF) leak and hypopituitarism Hypogonadism"}
{"id": "article-23208_34", "title": "Hyperprolactinemia -- Consultations", "content": "Endocrinologist Neurosurgeon Radiation Oncologist Psychiatrist Gynecologist", "contents": "Hyperprolactinemia -- Consultations. Endocrinologist Neurosurgeon Radiation Oncologist Psychiatrist Gynecologist"}
{"id": "article-23208_35", "title": "Hyperprolactinemia -- Deterrence and Patient Education", "content": "Prolactin is one of the hormones secreted by the pituitary gland. Different conditions cause increased secretion of prolactin. The important cause of increased prolactin secretion is a noncancerous\u00a0tumor of the pituitary gland called a prolactinoma. It can commonly cause menstrual irregularity, milk secretion from the breast, weak bone, headache, and visual field defects. MRI of the brain may be\u00a0required for the evaluation. This can be\u00a0treated\u00a0successfully with medical therapy alone which normalizes prolactin concentration and also reduces the size of the tumor. In a minority of cases, medication is not effective and should be treated with surgery and rarely with radiation.", "contents": "Hyperprolactinemia -- Deterrence and Patient Education. Prolactin is one of the hormones secreted by the pituitary gland. Different conditions cause increased secretion of prolactin. The important cause of increased prolactin secretion is a noncancerous\u00a0tumor of the pituitary gland called a prolactinoma. It can commonly cause menstrual irregularity, milk secretion from the breast, weak bone, headache, and visual field defects. MRI of the brain may be\u00a0required for the evaluation. This can be\u00a0treated\u00a0successfully with medical therapy alone which normalizes prolactin concentration and also reduces the size of the tumor. In a minority of cases, medication is not effective and should be treated with surgery and rarely with radiation."}
{"id": "article-23208_36", "title": "Hyperprolactinemia -- Enhancing Healthcare Team Outcomes", "content": "The healthcare professionals, acting as an interprofessional team, should educate the patient about the causes of hyperprolactinemia. If they diagnose the patient with prolactinoma, they should counsel the patient on symptoms of a\u00a0prolactinoma and when to seek help. There should be effective coordination between endocrinologists and neurosurgeons, and with a psychiatrist, if hyperprolactinemia is the result of the action of dopamine-antagonist drugs. A pharmacist has a role in educating patients on the effectiveness of medication and side effects, and coordinating with the clinicians on drug therapy going forward, including agent selection, dosing, and potential interactions. Oncology nurses should take part to inform the\u00a0patient about the possible need for radiation therapy for a large mass and the possibility of hypopituitarism. [26] [27] These interprofessional actions will drive better outcomes in hyperprolactinemia cases. [Level 5]", "contents": "Hyperprolactinemia -- Enhancing Healthcare Team Outcomes. The healthcare professionals, acting as an interprofessional team, should educate the patient about the causes of hyperprolactinemia. If they diagnose the patient with prolactinoma, they should counsel the patient on symptoms of a\u00a0prolactinoma and when to seek help. There should be effective coordination between endocrinologists and neurosurgeons, and with a psychiatrist, if hyperprolactinemia is the result of the action of dopamine-antagonist drugs. A pharmacist has a role in educating patients on the effectiveness of medication and side effects, and coordinating with the clinicians on drug therapy going forward, including agent selection, dosing, and potential interactions. Oncology nurses should take part to inform the\u00a0patient about the possible need for radiation therapy for a large mass and the possibility of hypopituitarism. [26] [27] These interprofessional actions will drive better outcomes in hyperprolactinemia cases. [Level 5]"}
{"id": "article-23208_37", "title": "Hyperprolactinemia -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Hyperprolactinemia -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}